

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: [ICC International Cannabis Corp.](#) (the "Issuer").

Trading Symbol: [WRLD.U](#)

Number of Outstanding Listed Securities: [443,518,296 common shares were issued and outstanding as of March 31, 2019.](#)

Date: [April 4, 2019 \(for the month of March 2019\)](#)

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

[The Issuer continues to evaluate potential marijuana projects and cannabis related companies for potential acquisition and growth. The Issuer continues to concentrate on assembling a robust portfolio of licences globally specializing in the cultivation, extraction and distribution of](#)

medical cannabis and CBD products with a specific emphasis on both the European Union and Latin American regions, and a keen interest in Africa and Australasia, Southeast Asia, and the Pacific Rim.

2. Provide a general overview and discussion of the activities of management.

During the month of March 2019, the Issuer:

- Closed a non-brokered private placement consisting of 42,187,500 units (“Units”) of the Company issued at a price of US\$0.32 per Unit and secured convertible debentures (the “Debentures”) for total gross proceeds of CAD\$45M (the “Offering”). The Issuer had paid a finder’s fees on this Offering.
 - Reaffirmed that it had been diligently working towards completing a Definitive Purchase Agreement (the “Definitive Agreement”) with Wayland Group Corp. as per the previously announced Letter of Intent (“LOI”).
 - Announced the formal integration of its Global Distribution Management System; the International Cannabis Exchange (“Intercannex”) into leading cannabis technology and security provider, Helix TCS, Inc. (“Helix”) (OTCQB: HLIX).
 - Entered into a licensing agreement with Authentic Brands Group (“ABG”), to market and distribute cannabidiol (“CBD”) derived health and wellness products throughout Europe, under the Marilyn Monroe®, Elvis Presley®, Greg Norman®, Tretorn®, Aéropostale® and Frederick’s of Hollywood® brands.
 - Added Thalia Sodi, world-renowned singer, songwriter and entrepreneur, to its existing licensing agreement with Authentic Brands Group, an owner of a portfolio of lifestyle and entertainment brands, including Ms. Sodi.
 - Announced its inclusion in the Horizons Medical Marijuana Life Sciences ETF (TSX: HMMJ) (the “ETF”), as part of the quarterly rebalance of the constituent holdings of HMMJ. Inclusion in the ETF is as a significant milestone for ICC, as the Company continues to establish itself as the world’s premier, vertically integrated pure cannabis play.
3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

There were no new products or services developed or offered during the month of March 2019.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

There were no products or services discontinued during the month of March 2019.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

On March 12, 2019, the Issuer had announced the formal integration of its Global Distribution Management System; the International Cannabis Exchange ("Intercannex") into leading cannabis technology and security provider, Helix TCS, Inc. ("Helix") (OTCQB: HLIX). The Companies will integrate Intercannex with Helix's industry-leading point-of-sale ("POS") system, BioTrackTHC. The unified platform will leverage the technological capabilities of Intercannex, a secure Electronic Cannabis Market ("ECM") to enable superior pricing, improved regulatory reporting and reduced costs. BioTrackTHC ranks as the #1 revenue-generating platform within the highly competitive dispensary POS category and has processed US\$18 billion in cannabis sales since inception.

On March 19, 2019, the Issuer had announced a licensing agreement with Authentic Brands Group ("ABG"), to market and distribute cannabidiol ("CBD") derived health and wellness products throughout Europe, under the Marilyn Monroe®, Elvis Presley®, Greg Norman®, Tretorn®, Aéropostale® and Frederick's of Hollywood® brands. The Issuer will leverage these widely recognized and trusted powerhouse brands that are already prominently featured on thousands of store shelves across Europe.

On March 22, 2019, the Issuer added Thalia Sodi, world-renowned singer, songwriter and entrepreneur, to its existing licensing agreement with Authentic Brands Group.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Not applicable to the Issuer during the month of March 2019.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

On March 19, 2019, the Issuer announced that it had entered into a licensing agreement with Authentic Brands Group ("ABG"), to market and distribute cannabidiol ("CBD") derived health and wellness products throughout Europe, under the Marilyn Monroe®, Elvis Presley®, Greg Norman®, Tretorn®, Aéropostale® and Frederick's of Hollywood® brands. The Issuer will leverage these widely recognized and trusted powerhouse brands that are already prominently featured on thousands of store shelves across Europe. The licensing agreement was executed on March 18, 2019 and extends for a ten-year term from the effective date. Under the terms of the licensing agreement with ABG, the Issuer will issue common shares with a value of \$2-million (U.S.) to ABG. The Issuer will also issue common shares with a value of \$15-million (U.S.) to CLP. The valuation of the shares will be based upon the five day VWAP of the Issuer's common shares for the five trading sessions prior to the announcement of the licensing agreement.

8. Describe the acquisition of new customers or loss of customers.
Not applicable to the Issuer during the month of March 2019.
9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.
Not applicable to the Issuer during the month of March 2019.
10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.
Not applicable to the Issuer during the month of March 2019.
11. Report on any labour disputes and resolutions of those disputes if applicable.
Not applicable to the Issuer during the month of March 2019.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Not applicable to the Issuer during the month of March 2019.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Not applicable to the Issuer during the month of March 2019.

14. Provide details of any securities issued and options or warrants granted.

During the month of March 2019, the Issuer issued 42,187,500 Units at a price of US \$0.32 per Unit. Each Unit is comprised of one common share (a "Share") and one-half of one transferable Share purchase warrant (each whole Share purchase warrant being a "Warrant"). Each Warrant shall entitle the holder thereof to purchase one additional Share of the Company at a price of US\$0.50 for a period of two years from the closing date.

The Debentures were issued at a deemed value of US \$0.38, which was the market price on March 6, 2019. The Debentures shall bear interest at a rate of 10.0% per annum from the date of issue, payable semi-annually in arrears on June 30 and December 31 of each year, commencing June 30, 2019. Interest shall be computed on the basis of a 360-day year composed of twelve 30-day months. The June 30, 2019 interest payment will represent accrued interest for the period from the closing date to June 30, 2019.

The Issuer had paid a finder's fees on this Offering.

Pursuant to the terms of a licensing agreement with ABG, the Issuer had issued common shares with a value of US\$2 million to ABG. Pursuant to a Consulting Agreement, the Issuer had issued common shares with a value of US\$15 million to Cannabis Lifestyle Partners ("CLP"), an arm's-length party. CLP provided advisory services to the Issuer and ABG. The valuation of the shares was based upon the five day VWAP of the Issuer's common shares for the five trading sessions prior to the announcement of the licensing agreement.

Security	Number Issued	Details of Issuance
Units	42,187,500	March 2019 Private Placement
Common Shares	52,307,692	Pursuant to terms of the CLP Consulting Agreement and the ABG Licensing Agreement

15. Provide details of any loans to or by Related Persons.

Not applicable to the Issuer during the month of March 2019.

16. Provide details of any changes in directors, officers or committee members.

Not applicable to the Issuer during the month of March 2019.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The trends and risks which are likely to impact the Issuer are detailed in the Issuer's Management Discussion & Analysis dated January 28, 2019 (the "MD&A"). The MD&A is available on the Issuer's SEDAR profile at www.sedar.com.

[the balance of this page is intentionally blank]

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated April 4, 2019.

Eugene Beukman
Name of Director or Senior
Officer

"Eugene Beukman"
Signature

Chief Executive Officer
Official Capacity

<i>Issuer Details</i> Name of Issuer ICC International Cannabis Corp	For Month End March 2019	Date of Report YY/MM/D 19/04/04
Issuer Address 810 – 789 West Pender Street		
City/Province/Postal Code Vancouver, BC V6C 1H	Issuer Fax No. 604-687-3141	Issuer Telephone No. 604-687-2308
Contact Name Eugene Beukman	Contact Position CEO, Director	Contact Telephone No. 604-782-4191
Contact Email Address Ebeukman@pendergroup.ca	Web Site Address N/A	